Latest Advances

  • Condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/MHNSCC)
  • Journal: Acta medica Okayama
  • Treatment Used: Nivolumab
  • Number of Patients: 0
  • Published —
This study assessed the utility of the neutrophil-to-lymphocyte ratio (NLR) and Glasgow Prognostic Score (GPS) as biomarkers of response to nivolumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/MHNSCC).
  • Condition: Head and Neck Cancer
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Radiation and Immunotherapy
  • Number of Patients: 21
  • Published —
The study researched the outcomes of radiation and immunotherapy for treating head and neck cancer.
  • Condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Journal: Frontiers in immunology
  • Treatment Used: Programmed Death-1/Programmed Death-Ligand 1(PD-1/PD-L1)-Axis Blockade
  • Number of Patients: 0
  • Published —
This review of the literature determined whether human papillomavirus (HPV) status is associated with improved clinical outcome of anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy in patients with head and neck squamous cell carcinoma (HNSCC).
  • Journal: BioMed research international
  • Published —
Selected E2F2 Polymorphisms in Oral and Oropharyngeal Squamous Cell Carcinoma.
  • Condition: Head and Neck Cancer
  • Journal: Laryngo- rhino- otologie
  • Treatment Used: Checkpoint Inhibitors
  • Number of Patients: 0
  • Published —
This article discusses the use of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.
Showing 1-12 of 359